All In Biotech

Drug Trial Radar · NCT06679946

A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

700

Planned (sponsor's estimate)

Start

Dec 3, 2024

Primary completion

Mar 31, 2028

Study completion Mar 31, 2028

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Nov 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from patisiran.

Conditions

  • Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Interventions

  • VutrisiranDrug

    Vutrisiran administered SC q3M

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Adverse Events (AEs)Time frame: Up to 36 Months

Locations

87 sites in 17 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Phoenix, Arizona

  • Clinical Trial Site

    Beverly Hills, California

  • Clinical Trial Site

    La Jolla, California

  • Clinical Trial Site

    Stanford, California

  • Clinical Trial Site

    Washington D.C., District of Columbia

  • Clinical Trial Site

    Chicago, Illinois

  • Clinical Trial Site

    Glenview, Illinois

  • Clinical Trial Site

    Indianapolis, Indiana

  • Clinical Trial Site

    Kansas City, Kansas

  • Clinical Trial Site

    Baltimore, Maryland

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Boston, Massachusetts

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    St Louis, Missouri

  • Clinical Trial Site

    Omaha, Nebraska

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    New York, New York

  • Clinical Trial Site

    Durham, North Carolina

  • Clinical Trial Site

    Cleveland, Ohio

  • Clinical Trial Site

    Columbus, Ohio

  • Clinical Trial Site

    Philadelphia, Pennsylvania

  • Clinical Trial Site

    Nashville, Tennessee

  • Clinical Trial Site

    Dallas, Texas

  • Clinical Trial Site

    Salt Lake City, Utah

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    Buenos Aires, Argentina

  • Clinical Trial Site

    Córdoba, Argentina

  • Clinical Trial Site

    Rosario, Argentina

  • Clinical Trial Site

    Rosario, Argentina

  • Clinical Trial Site

    Rosario, Argentina

  • Clinical Trial Site

    Vienna, Austria

  • Clinical Trial Site

    Vienna, Austria

  • Clinical Trial Site

    Aalst, Belgium

  • Clinical Trial Site

    Anderlecht, Belgium

  • Clinical Trial Site

    Dendermonde, Belgium

  • Clinical Trial Site

    Ghent, Belgium

  • Clinical Trial Site

    Hasselt, Belgium

  • Clinical Trial Site

    Leuven, Belgium

  • Clinical Trial Site

    Liège, Belgium

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.